The Siglecs reduce inflammation in conditions ranging from sepsis to autoimmunity and allergies. Antibodies, recombinant ligands, nanoparticles, or liposomes may be used to specifically fight detrimental inflammatory responses by siglec agonism. Potential as Siglec agonists may be shown in recombinant Siglec ligands. The finest illustration of this strategy is the expanding understanding of Siglec-10 as a crucial regulator of innate immune responses.
Siglec-10 on dendritic cells interacted with CD24 to lessen responses to damage-related molecular patterns. Recombinant CD24 might activate Siglec-G to stop harmful inflammation in a mouse model of graft-versus-host disease, according to some later studies. Due to this discovery, a company developed soluble CD24 that was provided as a dimer by conjugating it to an immunoglobulin Fc domain (CD24Fc) and acting as a Siglec-10 agonist. In the adaptive immune system, where the interaction of Siglec-10 on T cells with soluble glycosylated CD52 has been discovered to protect mice against type I diabetes, Siglec-10 agonism may potentially be beneficial. In non-human primate animal models, P-selectin inhibition with a recombinant P-selectin ligand reduced thrombosis.
Fig.1 Recombinant Siglec ligand. (Smith & Bertozzi, 2021)
New kinds of immunotherapeutics that target CD22 are currently being developed. Some drugs have been used in recombinant engineering to create multivalent and bispecific antibodies (bsAbs). These bsAbs worked in the absence of a secondary cross-linking antibody and at nanomolar doses. The bsAb-antigen complex does not undergo endocytosis while engaging CD22 as a result of concurrently binding to CD20, which most likely results in persistent CD22 signaling. It's tempting to think that such ground-breaking research on CD22 will serve as a model for treatment approaches aimed at additional Siglec members in the future. CD BioGlyco has advanced Antibody Development Platforms for customers to study recombinant Siglec ligands agonists.
Fig.2 CD22 structure and signaling pathway. (Aujla, et al., 2019)
CD BioGlyco provides powerful tools, such as Sialic Acid Microarray, Lectin Microarray, and Sialic Acid-Specific Lectin, to study the roles of recombinant Siglec ligands agonists and its Siglecs. And we have professional team of scientists, if you are interested in our services, please feel free to contact us. We look forward to inquiries from customers around the world.
References:
